Hoffman, J. E., Bumma, N., Richter, J., Dhodapkar, M. V., Lee, H. C., Suvannasankha, A., Houde, C. A., Maly, J. J., Shah, M. R., Baz, R., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Lentzsch, S., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Jagannath, S. (2023). Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment. Blood, 142(Supplement 1), 3359–3359. https://doi.org/10.1182/blood-2023-179170

Mohite, P., Nahar, D., Pawara, R., Alqahtani, T., Eldin, S. M., Mukherje, N., Rahman Mohammad Said Al-Tawaha, A., Iqbal, R., Bawazeer, S., & Ali, I. (2023). Triazolopyridine, a leitmotif of synthetic methods and pharmacological attributes: An extensive review. Arabian Journal of Chemistry, 16(10), 105181. https://doi.org/10.1016/j.arabjc.2023.105181

Chakraborty, R., Yan, Y., & Royal, M. (2021). A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 138(Supplement 1), 4763–4763. https://doi.org/10.1182/blood-2021-150783